- Report
- October 2025
- 192 Pages
Global
From €3171EUR$3,545USD£2,789GBP
€3523EUR$3,939USD£3,099GBP
- Report
- October 2025
- 309 Pages
Global
From €5233EUR$5,850USD£4,603GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €894EUR$1,000USD£787GBP
€1118EUR$1,250USD£983GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1431EUR$1,600USD£1,259GBP
€1789EUR$2,000USD£1,574GBP
- Report
- March 2024
- 200 Pages
Global
From €3712EUR$4,150USD£3,265GBP
- Report
- June 2024
- 200 Pages
Global
From €5689EUR$6,360USD£5,004GBP
€7111EUR$7,950USD£6,255GBP
- Report
- April 2023
- 120 Pages
Global
From €4249EUR$4,750USD£3,737GBP
- Report
- May 2024
- 137 Pages
Global
From €4941EUR$5,524USD£4,346GBP
€5813EUR$6,499USD£5,113GBP
- Report
- February 2023
- 152 Pages
Global
From €2236EUR$2,500USD£1,967GBP
- Report
- October 2022
- 94 Pages
Global
From €1789EUR$2,000USD£1,574GBP
Kaposi Sarcoma (KS) is a type of cancer that affects the skin and other organs. It is caused by the human herpesvirus 8 (HHV-8). Treatment for KS typically involves chemotherapy, radiation therapy, and/or biologic therapy. Oncology drugs are used to treat KS, and the Kaposi Sarcoma Drug market is a subset of the larger Oncology Drug market.
The Kaposi Sarcoma Drug market is composed of drugs used to treat KS, including chemotherapy drugs, biologic therapies, and other treatments. These drugs are used to reduce the size of tumors, reduce symptoms, and improve quality of life. The market is highly competitive, with many companies offering different treatments.
Some companies in the Kaposi Sarcoma Drug market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. These companies offer a variety of treatments for KS, including chemotherapy drugs, biologic therapies, and other treatments. Show Less Read more
